Category: NEC
-
Abbott Labs stock ‘attractive entry’ amid NEC litigation overhang
•
On Thursday, Piper Sandler began covering Abbott Laboratories (NYSE:NYSE:) stock, assigning an Overweight rating and a $131 price target. The company highlighted the company’s strong performance, but noted that the stock has underperformed year-to-date, largely due to ongoing litigation related to necrotizing enterocolitis (NEC). However, the company believes that the…